Irish biopharmaceutical company: Jazz Pharmaceuticals (JAZZ) (2003)

Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) was founded in 2003 and is headquartered in Dublin, Ireland, with 885 full-time employees. It is a commercial biopharmaceutical company engaged in the identification, development and commercial application of pharmaceutical products.

Jazz Pharmaceuticals Logo

Jazz Pharmaceuticals (JAZZ):

Jazz Pharmaceuticals is a professional biopharmaceutical company, mainly engaged in the participation, research and development and sales of various medical drugs in the United States, Europe and internationally. Jazz Pharmaceuticals products include:

  1. Xyrem-used to treat patients with narcolepsy-cataplexy/narcolepsy (EDS) medication;
  2. Erwinaze-used to treat acute lymphatic leukemia;
  3. Defitelio-for the treatment and prevention of hepatic venous obstructive disease (VOD), a potentially fatal complication after hematopoietic stem cell transplantation (HSCT);
  4. Prialt-used to treat severe chronic pain;
  5. FazaClo LD-medication for schizophrenia;
  6. FazaClo HD tablets;
  7. Versacloz;
  8. JZP-110-used to treat patients with narcolepsy (EDS)-clinical stage;
  9. JZP-386-sodium oxybate product, modified deuterium analogue, used in the treatment of narcolepsy-clinical stage;
  10. Asparec-for the treatment of acute lymphoblastic leukemia (ALL) and E. coli-aspartame allergy-Phase I clinical trial stage;
  11. Defibrotide-for the treatment of severe hepatic venous obstructive disease (VOD)-clinical trial stage;
  12. Leukotac-an anti-CD25 monoclonal antibody for the treatment of steroid-ineffective acute graft-versus-host reaction-Phase III clinical trial phase.

History of Jazz Pharmaceuticals (JAZZ):

  • In 2003, Jazz Pharmaceuticals was established;
  • In 2005, Jazz Pharmaceuticals acquired Orphan Medical and its product-Xyrem ® ;
  • In 2007, Jazz Pharmaceuticals released Luvox CR ® ;
  • On September 19, 2011, Jazz Pharmaceuticals agreed to the merger of Azur Pharma, and the transaction was completed in 2012, bringing the company a new product-Prialt ® ;
  • In 2012, Jazz Pharmaceuticals acquired EUSA Pharma for US$650 million, including its products-Erwinaze ® /Erwinase ® ;
  • In 2013, Jazz Pharmaceuticals and Concert Pharmaceuticals (NASDAQ:CNCE) agreed to develop JZP-386;
  • In 2014, Jazz Pharmaceuticals acquired JZP-110 development rights from Aerial BioPharma;
  • In 2014, Jazz Pharmaceuticals acquired Gentium for US$1 billion, including its product Defitelio ® (defibrotide);
  • In 2014, Jazz Pharmaceuticals acquired the US patent right of Defitelio ® (defibrotide) from Sigma-Tau Pharma ;
  • In 2015, Jazz Pharmaceuticals started a phase III clinical trial of JZP-110;
  • On May 31, 2016, biopharmaceutical company Jazz announced the acquisition of pharmaceutical company Celator for US$1.5 billion to obtain its investigational drug for the treatment of acute myeloid leukemia. The transaction was completed in July of the same year.
Notify of
Inline Feedbacks
View all Intels

Israeli retailer: Alon Blue Square Israel (BSI) (1988)

The world’s third largest agricultural machinery manufacturer: AGCO Corporation (AGCO) (1990)